How often do I need to take Semaglutide GLP-1 injections for weight loss
DTSQ = Diabetes Treatment Satisfaction Questionnaire
2024:e13700
Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA , Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA
Medications that are classified as glucagon-like peptide-1 (GLP-1) receptor agonists might increase surgical risks for patients who are receiving general anesthesia or deep sedation
Carmot Therapeutics is also advancing preclinical programs targeting PYY, a peptide for potentially treating Prader Willi syndrome and other metabolic diseases in conjunction with other incretin agonists